- Rheumatoid Arthritis (RA) – adults, with or without methotrexate
- Psoriatic Arthritis (PsA)
- Ankylosing Spondylitis (AS)
Dose:50 mg SC once weekly (or 25 mg SC twice weekly, 3–4 days apart)
- Plaque Psoriasis – moderate to severe, adults & children ≥4 years
Dose: Plaque Psoriasis (≥4 years):0.8 mg/kg weekly (max 50 mg/week)
- Polyarticular Juvenile Idiopathic Arthritis (JIA) – ages ≥2 years
Dose: JIA (≥2 years):0.8 mg/kg once weekly (max 50 mg/week)
- Prefilled Syringes / Auto-injectors:
- 25 mg/0.5 mL, 50 mg/mL
- Lyophilized Powder for Reconstitution:
- 25 mg per vial
- Subcutaneous injection only (abdomen, thigh, upper arm)
- Rotate injection sites
- Refrigerate; allow to reach room temp before injection
- Do not shake
- Do not use if cloudy or discolored
- Class: TNF-α inhibitor (fusion protein)
- Mechanism of Action:
- Soluble receptor fusion protein: binds TNF-α, preventing interaction with receptors
- ↓ inflammatory cytokines, immune cell activation
- Half-life: ~3–5 days
- Peak levels: 48–60 hours post-injection
- Excretion: Unknown; not cleared by kidneys
- Injection site reactions (pain, redness, itching)
- Infections (URIs, sinusitis)
- Headache
- Nausea
- Rash
- Sepsis or risk of life-threatening infections
- Known hypersensitivity to etanercept or components
- Avoid live vaccines during and after treatment
- Do not combine with other biologics (e.g., infliximab, adalimumab)
- May be used with methotrexate
- Additive immunosuppressive effect with cyclosporine, corticosteroids
Drug Status
Availability | |
Pregnancy | |
Breastfeeding | |
Schedule |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Enbrel | 25mg | Pre-Filled Syringe | 1’s | Pfizer Labs | Pfizer Labs |
Enbrel | 50mg | Pre-Filled Syringe | 1’s | Pfizer Labs | Pfizer Labs |